Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia
NCT ID: NCT01323374
Last Updated: 2024-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
122 participants
INTERVENTIONAL
2009-01-31
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
As this benefit is presumed to be a central effect, the addition of carbidopa, a peripheral DOPA decarboxylase (DDC) inhibitor, may favorably impact the drug's treatment profile. Carbidopa is utilized as a blocker of peripheral DDC, an enzyme required for the conversion of droxidopa into norepinephrine. Therefore, inhibition of peripheral DDC should result in a reduction of any side effects resulting from the peripheral production of norepinephrine, whilst allowing for increased central levels, and hence, increased centrally mediated benefits.
The purpose of the study is the obtain information regarding the proper dosing, effectiveness and safety of droxidopa and combination droxidopa/carbidopa treatments in patients with fibromyalgia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Duloxetine Versus Placebo in the Treatment of FMS
NCT00233025
The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia
NCT07171320
A Study of Duloxetine in Fibromyalgia
NCT01552057
Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome
NCT00190866
The Effect of Sympathetic Dysfunction on Muscle Spindle in Fibromyalgia
NCT05704374
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
While there is debate as to specific etiology and pathogenesis, fibromyalgia is generally believed to be the result of a perturbation of central pain processing, specifically the neuroendocrine system. Fibromyalgia patients have been shown to have lower levels of metabolites from three neurotransmitters (serotonin, norepinephrine, and dopamine) in their cerebrospinal fluid (CSF) compared to healthy controls. The low rate of turnover of these neurotransmitters supports the hypothesis of a metabolic defect in fibromyalgia and suggests that the defect occurs at a neuroregulatory level. Results of a study that examined the effect of a permanent reduction in the noradrenergic innervation of the spinal cord suggested that the antinociceptive effects of norepinephrine are closely linked to opioidergic and tachykinergic neurotransmission.
Droxidopa \[also, known as L-threo-3,4-dihydroxyphenylserine, L-threo-DOPS, or L-DOPS\] is the International non-proprietary name (INN) for a synthetic amino acid precursor of norepinephrine (NE), which was originally developed by Sumitomo Pharmaceuticals Co., Limited, Japan. It has been approved for use in Japan since 1989. Droxidopa has been shown to improve symptoms of orthostatic hypotension that result from a variety of conditions including Shy Drager syndrome (Multiple System Atrophy), Pure Autonomic Failure, and Parkinson's disease. There are four stereoisomers of DOPS; however, only the L-threo-enantiomer (droxidopa) is biologically active. Data from clinical studies and post-marketing surveillance programs conducted in Japan show that the most commonly reported adverse drug reactions with droxidopa are increased blood pressure, nausea, and headache. In clinical studies to date, data suggests that droxidopa is well-tolerated and effective as a norepinephrine precursor.
Pre-clinical and clinical studies suggest that droxidopa has an analgesic effect in patients with chronic pain. An increase in central nervous system (CNS) levels of norepinephrine has been shown to correlate with an analgesic effect. Based on the pre-clinical and clinical findings to date, it is hypothesized that droxidopa can provide pain reduction in fibromyalgia patients through increasing the CNS levels of norepinephrine.
Carbidopa is a DOPA decarboxylase (DDC) inhibitor. At therapeutic doses carbidopa does not cross the blood-brain barrier and therefore should not inhibit CNS metabolism of droxidopa to NE. Decreasing the activity of DDC in the periphery enables droxidopa metabolism to be focused in the CNS. This CNS focus should increase CNS response while also limiting the increase in blood pressure associated with peripheral droxidopa metabolism. In addition, as DDC is an enzyme required for the conversion of droxidopa into its active metabolite norepinephrine, inhibition of peripheral DDC, utilizing Carbidopa, should result in a reduction of any side effects resulting from the peripheral production of NE, whilst allowing for increased central levels, and hence, increased centrally mediated benefits.
The primary objective of this study is to determine the efficacy of droxidopa and droxidopa/carbidopa in the treatment of pain associated with fibromyalgia. Secondary objectives include: evaluation of the effect of droxidopa and combinations of droxidopa/carbidopa on signs and symptoms of fibromyalgia, evaluation of the effect of droxidopa and combinations of droxidopa/carbidopa on the overall quality of life of fibromyalgia patients, evaluation of the dose-response relationship for droxidopa between different doses of droxidopa, carbidopa and combinations of droxidopa/carbidopa in fibromyalgia patients, evaluation of the clinical benefit of treatment with different doses of droxidopa, carbidopa and combinations of droxidopa/carbidopa in fibromyalgia patients, estimation of the optimal dose for relief of fibromyalgia pain using response surface methodology, and evaluation of the safety of droxidopa and droxidopa/carbidopa treatments.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Droxidopa 200mg TID
Droxidopa
Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
Droxidopa 400mg TID
Droxidopa
Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
Droxidopa 600mg TID
Droxidopa
Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
Carbidopa 25mg TID
Carbidopa
Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
Carbidopa 50 mg TID
Carbidopa
Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
Droxidopa/carbidopa 200mg/25mg TID
Droxidopa/carbidopa
Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
Droxidopa/carbidopa 400mg/25mg TID
Droxidopa/carbidopa
Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
Droxidopa/carbidopa 600mg/25mg TID
Droxidopa/carbidopa
Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
Droxidopa/carbidopa 200mg/50mg TID
Droxidopa/carbidopa
Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
Droxidopa/carbidopa 400mg/50mg TID
Droxidopa/carbidopa
Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
Droxidopa/carbidopa 600mg/50mg TID
Droxidopa/carbidopa
Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
Placebo TID
Placebo
Oral, placebo TID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Droxidopa
Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
Carbidopa
Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
Droxidopa/carbidopa
Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
Placebo
Oral, placebo TID
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of fibromyalgia as defined by the 1990 American College of Rheumatology (ACR) criteria
* Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care
* Have a score of between 20mm and 90mm on the Visual Analog Scale for Pain (VAS-P) section of the SF-MPQ at screening and baseline visits
Exclusion Criteria
* Patients currently taking pregabalin; unless they provide written informed consent and agree to discontinue pregabalin use 3 weeks prior to other screening procedures and for the duration of the study
* Currently taking tri-cyclic antidepressant medication
* Currently taking any norepinephrine re-uptake inhibitors
* Have clinically relevant depression noted as significant by a score greater than 17 on the Hamilton Depression Scale (HAM-D)
* History of known or suspected drug or substance abuse
* Women of childbearing potential who are not using a medically accepted contraception (Reproductive potential: Female subjects should be either post-menopausal (amenorrhea for at least 12 consecutive months), surgically sterile, or women of child-bearing potential (WOCP) who are using or agree to use acceptable methods of contraception throughout the study period and for 4 weeks after the last dose of investigational product. Acceptable contraceptives include intrauterine devices (IUDs), hormonal contraceptives (oral, depot, patch or injectable) and double barrier methods such as condoms or diaphragms with spermicidal gel or foam. If hormonal contraceptives are used they should be taken according to the package insert. WOCP who are not currently sexually active must agree to use acceptable contraception, as defined above, if they decide to become sexually active during the period of the study and for 4 weeks after the last dose of investigational product. For WOCP a urine pregnancy test must be conducted at screening, baseline and study termination; the results must be negative at screening and at baseline. Any positive result will be confirmed by serum beta HCG pregnancy test).
* Sexually active males whose partner is a WOCP must agree to use condoms for the duration of the study and for 4 weeks after the last dose
* Women who are pregnant, breast feeding, or plan to become pregnant during the course of this study
* Known or suspected hypersensitivity to the study medication or any of its ingredients
* Have in the investigator's opinion any significant cardiac arrhythmia
* Any significant systemic, hepatic, cardiac or renal illness
* Diabetes mellitus or insipidus
* Have a history of closed angle glaucoma
* Have a known or suspected current malignancy. Patients with a history of cancer must be symptom- and treatment-free for at least 5 years prior to randomization, with the exception of patients with non-melanoma, non-invasive skin cancers (such as basal cell carcinoma), who should not have had an intervention or recurrence within one year of starting the study
* Patients with known gastrointestinal illness or other gastrointestinal disorder that may, in the investigator's opinion, affect the absorption of study drug
* In the investigator's opinion, have clinically significant abnormalities on clinical examination or laboratory testing
* In the investigator's opinion, are unable to adequately co-operate because of individual or family situation
* In the investigator's opinion, are suffering from a mental disorder that interferes with the diagnosis and/or with the conduct of the study, e.g. schizophrenia, major depression, dementia
* Are not able or willing to comply with the study requirements for the duration of the study
* Have participated in another clinical trial with an investigational agent (including named patient or compassionate use protocol) within 1 month before the start of the study
* Previous enrollment in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chelsea Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ernest Choy, M.D.
Role: PRINCIPAL_INVESTIGATOR
Academic Dept of Rheumatology Kings College London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rheumatology Department; Barnsley Hospital NHS Foundation Trust
Barnsley, , United Kingdom
MAC UK Neuroscience
Liverpool, , United Kingdom
Academic Dept of Rheumatology, Kings College London
London, , United Kingdom
MAC UK Neuroscience
Manchester, , United Kingdom
Musculoskeletal Department; Freeman Hospital
Newcastle upon Tyne, , United Kingdom
Rheumatology Department, Poole Hospital NHS Trust
Poole, , United Kingdom
Clinical Trials Unit; Main Hospital; Salford Rooyal NHS Foundation Trust
Salford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
EudraCT summary results
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Droxidopa FMS201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.